Stretched by business that already arrived: the company is visibly catching up to demand it has in hand
The model's full reasoning — Q3 2018 call → NOWe need to determine if the transcript conveys that the company is currently being stretched or reshaped by real business that has already arrived or is already committed, and that the company is actively catching up to it, with the full effect of that business still ahead of the reported results. Let's analyze the transcript. Key points: - Revenue for Q3 fiscal 2018 was $22.2 million, up 25% from prior year. This includes $1.7 million from SurVeil agreement with Abbott. - They updated fiscal 2018 revenue guidance to $79-81 million, up from $75-79 million. - They mention "solid top-line performance" and "operational results as we continue to invest in our new product pipeline." - They talk about the SurVeil agreement with Abbott, which is a major partnership. They are supplying the SurVeil Drug-Coated Balloon to Abbott and collaborating on development, clinical trials, regulatory. They mention "The collaboration with Abbott team on ongoing development for SurVeil and the partnership itself is going exceptionally well." - They talk about the TRANSCEND clinical trial for SurVeil, progressing nicely, with sites being initiated, enrollment progressing. They expect to complete enrollment by end of fiscal 2019. - They mention "We are well on our way to having all U.S. clinical sites initiated by the end of fiscal 2018 as planned." - They also mention the Embolitech acquisition of thrombectomy technology, which they are developing, with expectations to submit for regulatory approval in first half of calendar 2020. - They talk about their pipeline of commercially approved products, including Telemark microcatheter, .014 PTA balloon, .018 balloon, etc. They are progressing towards commercial agreements with several interested parties. They are conducting clinical evaluations. - They mention "We continue to have active and ongoing strategic in this product for multiple parties who are conducting their own clinical evaluation." for Telemark.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| NOAH | Noah Holdings Limited | Q1 2024 | 2024-05-30 | D |
| ROCK | Gibraltar Industries, Inc. | Q1 2024 | 2024-05-01 | B+ |
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| GIII | G-III Apparel Group, Ltd. | Q4 2024 | 2024-03-14 | C |
| MNKD | MannKind Corporation | Q4 2023 | 2024-02-27 | C |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| TGLS | Tecnoglass Inc. | Q2 2023 | 2023-08-08 | A |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| KE | Kimball Electronics, Inc. | Q3 2023 | 2023-05-06 | C+ |
| TSSI | TSS, Inc. | Q4 2022 | 2023-04-03 | D |
| TACT | TransAct Technologies Incorporated | Q4 2022 | 2023-03-08 | A |
| ADM | Archer-Daniels-Midland Company | Q4 2022 | 2023-01-26 | C+ |
| SIBN | SI-BONE, Inc. | Q3 2022 | 2022-11-07 | C+ |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| IT | Gartner, Inc. | Q2 2022 | 2022-08-02 | A |
| JBHT | J.B. Hunt Transport Services, Inc. | Q2 2022 | 2022-07-19 | C+ |
| FLUX | Flux Power Holdings, Inc. | Q2 2022 | 2022-02-10 | D |
| GTES | Gates Industrial Corporation plc | Q4 2021 | 2022-02-07 | C+ |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| HNRG | Hallador Energy Company | Q3 2021 | 2021-11-09 | C+ |
| KTB | Kontoor Brands, Inc. | Q3 2021 | 2021-11-04 | A |
| BC | Brunswick Corporation | Q3 2016 | 2016-10-28 | B+ |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
ROCK · Q1 2024 → YESThe question is: Does management convey that the company is CURRENTLY BEING STRETCHED OR RESHAPED BY REAL BUSINESS THAT HAS ALREADY ARRIVED OR IS ALREADY COMMITTED — and that the company is actively c...YES The transcript shows management describing real, already-committed business pressure in renewables (rapid 1P tracker uptake and customer switches creating redesign delays and revenue push into Q2/H2) while they are actively catching up by ramping supply chain capacity sooner than planned. In Agtech, $40M+ new orders signed in April (previously expected in Q1) are now starting in Q2 and accelerating later, with execution ramping ahead of full revenue impact. These details convey the company is being reshaped by arrived committed work, with today's results reflecting only the early portion of that business.
MNKD · Q4 2023 → YESThe question is: Does management convey that the company is CURRENTLY BEING STRETCHED OR RESHAPED BY REAL BUSINESS THAT HAS ALREADY ARRIVED OR IS ALREADY COMMITTED — and that the company is actively c...YES The transcript shows Tyvaso DPI as the clearest example. Management states they are “making as much as we can around the clock,” have just completed qualification of the high-speed fill-finish line, and are entering PPQ to produce “much higher volumes.” They explicitly note they want to “build up inventory as well” because demand already exceeds current manufacturing capacity, and they will have “equal record production in Q1 and even more production in Q2.
CRL · Q2 2022 → YESThe question is whether management conveys that the company is currently being stretched or reshaped by real business that has already arrived or is already committed, and they're actively catching up...YES The transcript shows management conveying exactly this situation for the Safety Assessment business (the core of DSA).